Cover Image

Corrigendum: Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach

Saved in:

Bibliographic Details
Main Authors:	Shuaibing Liu (Author), Ziteng Wang (Author), Xin Tian (Author), Weimin Cai (Author)
Format:	Book
Published:	Frontiers Media S.A., 2021-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach
by: Shuaibing Liu, et al.
Published: (2020)

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers
by: Xiaojiao Li, et al.
Published: (2018)

Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen
by: Ioannis Loisios-Konstantinidis, et al.
Published: (2020)

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
by: Uta Schilling, et al.
Published: (2022)

Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers
by: Xinwen Wang, et al.
Published: (2021)

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists
by: Andrea Henrich, et al.
Published: (2021)

Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
by: Caifu Xue, et al.
Published: (2017)

Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans
by: Jinfang Jiang, et al.
Published: (2017)

Effect of CYP3A4 Inhibitors and Inducers on Pharmacokinetics and Pharmacodynamics of Saxagliptin and Active Metabolite M2 in Humans Using Physiological-Based Pharmacokinetic Combined DPP-4 Occupancy
by: Gang Li, et al.
Published: (2021)

Understanding inter-individual variability in pharmacokinetics/pharmacodynamics of aripiprazole in children with tic disorders: Individualized administration based on physiological development and CYP2D6 genotypes
by: Yingying Xin, et al.
Published: (2022)

Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of codeine in different CYP2D6 phenotypes
by: Yujie Yang, et al.
Published: (2024)

Torsemide Pharmacometrics in Healthy Adult Populations Including CYP2C9 Genetic Polymorphisms and Various Patient Groups through Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling
by: Seung-Hyun Jeong, et al.
Published: (2022)

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling
by: Laura Maria Fuhr, et al.
Published: (2022)

Elucidation of catalytic property and structural feature of human carboxylesterase2
by: Sou Tanoue, et al.
Published: (2012)

Pharmacokinetics, pharmacodynamics, and safety of ciprofol emulsion in Chinese subjects with normal or impaired renal function
by: Jun Tao, et al.
Published: (2023)

Randomized evaluation of the loss‐of‐function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics
by: Joshua P. Lewis, et al.
Published: (2024)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
by: Frost C, et al.
Published: (2018)

Physiologically-Based Pharmacokinetic-Pharmacodynamics Model Characterizing CYP2C19 Polymorphisms to Predict Clopidogrel Pharmacokinetics and Its Anti-Platelet Aggregation Effect Following Oral Administration to Coronary Artery Disease Patients With or Without Diabetes
by: Ru-jun Xu, et al.
Published: (2020)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
by: Laura Maria Fuhr, et al.
Published: (2021)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2022)

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
by: Jan Grzegorzewski, et al.
Published: (2022)

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of CYP2D6‐Mediated Gene-Drug-Drug Interactions
by: Flavia Storelli, et al.
Published: (2019)

Species comparison of pre-systemic bioactivation of vicagrel, a new acetate derivative of clopidogrel
by: Zhi xia Qiu, et al.
Published: (2016)

Human carboxylesterases: a comprehensive review
by: Dandan Wang, et al.
Published: (2018)

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
by: Guoliang Deng, et al.
Published: (2023)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
by: Lozano R, et al.
Published: (2013)

Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis
by: Carlijn H. C. Litjens, et al.
Published: (2023)

Population pharmacokinetic‐pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study
by: Yun Seob Jung, et al.
Published: (2024)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
by: Cui Y, et al.
Published: (2014)

A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity
by: Janna K. Duong, et al.
Published: (2022)

Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups
by: Simeon Rüdesheim, et al.
Published: (2022)

Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population
by: Elizabeth J. Thompson, et al.
Published: (2024)

Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone
by: Simeon Rüdesheim, et al.
Published: (2022)

Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions
by: Simeon Rüdesheim, et al.
Published: (2020)

Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates
by: Reisman SA, et al.
Published: (2019)

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug-drug-gene interaction network
by: Denise Feick, et al.
Published: (2023)

Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone antagonist in healthy premenopausal women
by: Yi Xu, et al.
Published: (2022)

An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation
by: Mariana Floria, et al.
Published: (2024)

Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib
by: Hongrui Liu, et al.
Published: (2022)

Carboxylesterase 2 induces mitochondrial dysfunction via disrupting lipid homeostasis in oral squamous cell carcinoma
by: Xijuan Chen, et al.
Published: (2022)